Aurobindo Pharma USA Receives FTC Approval to Acquire Generic Pharmaceutical Company Lannett

Aurobindo Pharma USA Receives FTC Approval to Acquire Generic Pharmaceutical Company Lannett​

Aurobindo Pharma USA, Inc., a wholly owned subsidiary of Aurobindo Pharma Limited, has received approval from the U.S. Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC. The transaction is valued at $250 million on a cash free debt free basis and is expected to close before the end of June 2026.

Lannett, which is based in Pennsylvania, operates as a generic pharmaceutical company specializing in the development and commercialization of complex non opioid controlled substances. This acquisition is set to significantly expand Aurobindo USA's product offering within this segment and adds a U.S. based manufacturing facility to its operational network.

The strategic importance of the deal includes strengthening domestic manufacturing capabilities. Lannett’s site located in Seymour, Indiana, has the capacity to scale production to approximately 4 billion doses annually. This expanded capability supports U.S. policy priorities focused on increasing domestic pharmaceutical production and improving supply chain resilience.

Beyond enhancing its portfolio with a differentiated pipeline of complex generics and controlled substances, the transaction is anticipated to generate cost efficiencies SG&A synergies and operational integration advantages, as well as being immediately accretive to Aurobindo Group's earnings per share.

Swami S Iyer, Chief Executive Officer of Aurobindo Pharma USA, stated that this acquisition represents a highly compelling strategic and financial opportunity for Aurobindo USA. He added that it accelerates revenue growth strengthens U.S.-based manufacturing capabilities and enhances the company's position in complex non opioid controlled substances. Iyer expressed confidence that the deal will deliver immediate earnings accretion while creating long term value for shareholders through operational synergies and pipeline expansion.

Tim Crew, Chief Executive Officer of Lannett Company, shared his excitement about joining forces with Aurobindo. He noted that as one of the nation's oldest generic pharmaceutical companies Lannett has a history of helping patients access affordable medicines. Crew believes that Aurobindo's market reach and resources will make their portfolio of medicines even more affordable and accessible for patients everywhere.

AUROPHARMA Stock Price Movement​

On Friday, Aurobindo Pharma Limited shares climbed robustly, settling at a gain of 3.87%, or ₹55.80. The equity saw significant investor interest, with millions of shares traded during the session.